

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

HEK-293T-hACE2

RRID:CVCL_A7UK

Type: Cell Line

Proper Citation

BEI_Resources Cat# NR-52511, RRID:CVCL_A7UK

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_A7UK

Proper Citation: BEI_Resources Cat# NR-52511, RRID:CVCL_A7UK

Description: Cell line HEK-293T-hACE2 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Female

Defining Citation: [PMID:33495308](#)

Comments: Characteristics: Expresses ACE2 under the control of the EF1a promoter (BEI_Resources=NR-52511)., Group: SARS-CoV-2 research cell line.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: HEK-293T-hACE2

Synonyms: 293T-ACE2

Cross References: BEI_Resources:NR-52511, Wikidata:Q107115255

ID: CVCL_A7UK

Vendor: BEI_Resources

Catalog Number: NR-52511

Hierarchy: cvcl_0063

Record Creation Time: 20250130T071613+0000

Record Last Update: 20260905T184022+0000

Ratings and Alerts

No rating or validation information has been found for HEK-293T-hACE2.

No alerts have been found for HEK-293T-hACE2.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 46 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen W, et al. (2026) Broad-spectrum coronavirus inhibition by RSV fusion inhibitors targeting six-helix bundle formation. Life sciences, 394, 124357.

Cohen AA, et al. (2026) mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures. Cell reports, 45(5), 117335.

Li P, et al. (2026) Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants. Journal of virology, 100(6), e0001626.

Gupta P, et al. (2026) Interaction and co-phase separation of SARS-CoV-2 nucleocapsid protein and human hnRNPA1 and its implications for viral life cycle. FEBS letters.

Cohen AA, et al. (2025) Broad anti-sarbecovirus responses elicited by a single administration of mosaic-8 RBD-nanoparticle vaccine prepared using atomic layer deposition. iScience, 28(11), 113649.

Cohen AA, et al. (2025) Single administration of mosaic-8b RBD-nanoparticle vaccine prepared with atomic layer deposition technology elicits broadly neutralizing anti-sarbecovirus responses. bioRxiv : the preprint server for biology.

Wang E, et al. (2025) Designed mosaic nanoparticles enhance cross-reactive immune responses in mice. Cell, 188(4), 1036.

Li P, et al. (2025) Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants. mBio, 16(5), e0046425.

Cohen AA, et al. (2025) mRNA delivery of genetically encoded mosaic-8 pan-sarbecovirus RBD vaccines. bioRxiv : the preprint server for biology.

Li P, et al. (2025) Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability. Journal of virology, 99(4), e0024225.

Johnson NV, et al. (2024) Discovery and characterization of a pan-betacoronavirus S2-binding antibody. Structure (London, England : 1993), 32(11), 1893.

Li P, et al. (2024) Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion. *mBio*, 15(5), e0075124.

Li P, et al. (2024) Characteristics of JN.1-derived SARS-CoV-2 subvariants SLip, FLiRT, and KP.2 in neutralization escape, infectivity and membrane fusion. *bioRxiv : the preprint server for biology*.

Cohen AA, et al. (2024) Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals. *Cell*, 187(20), 5554.

Cohen AA, et al. (2024) Mosaic sarbecovirus vaccination elicits cross-reactive responses in pre-immunized animals. *bioRxiv : the preprint server for biology*.

Li P, et al. (2024) Neutralization and Stability of JN.1-derived LB.1, KP.2.3, KP.3 and KP.3.1.1 Subvariants. *bioRxiv : the preprint server for biology*.

Faraone JN, et al. (2024) Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination. *Journal of medical virology*, 96(3), e29520.

Li P, et al. (2024) Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion. *bioRxiv : the preprint server for biology*.

Li P, et al. (2024) Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants. *Cell reports*, 43(8), 114520.

Li P, et al. (2024) Immune Evasion, Cell-Cell Fusion, and Spike Stability of the SARS-CoV-2 XEC Variant: Role of Glycosylation Mutations at the N-terminal Domain. *bioRxiv : the preprint server for biology*.